897 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Buy
Article Searches
Chowing On Unsafe Dividends For Monday's Breakfast http://seekingalpha.com/article/3475696-chowing-on-unsafe-dividends-for-mondays-breakfast?source=feed_all_articles Aug 28, 2015 - I want to provide investors a live look at my portfolio management practices during periods of significant volatility.
Veeva Beats Q2 Earnings on Strong Revenues, Guides Up http://www.zacks.com/stock/news/188124/veeva-beats-q2-earnings-on-strong-revenues-guides-up?cid=CS-ZC-FT-188124 Aug 28, 2015 - Veeva Systems Inc. (VEEV) reported adjusted earnings of 10 cents per share in the second quarter of fiscal 2016, in line with the Zacks Consensus Estimate
Premarket Biotech Digest: Geron EDP Today, Repatha Approval, Mylan Perrigo Deal http://seekingalpha.com/article/3473996-premarket-biotech-digest-geron-edp-today-repatha-approval-mylan-perrigo-deal?source=feed_sector_healthcare Aug 28, 2015 - I will be holding an expert discussion panel on Geron today.
TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial http://seekingalpha.com/article/3471356-tigenix-achieves-first-ever-success-in-allogeneic-stem-cell-phase-3-trial?source=feed_tag_long_ideas Aug 27, 2015 - TiGenix's pivotal Phase 3 trial in Europe met its primary endpoint in an indication targeting a potential $2 billion orphan market.
A Pivotal Moment For GlaxoSmithKline http://seekingalpha.com/article/3467576-a-pivotal-moment-for-glaxosmithkline?source=feed_sector_healthcare Aug 27, 2015 - Glaxo stock has declined due to patent expirations and negative investor sentiment, which offers opportunistic investors a reasonable buying opportunity.
Premarket Biotech Digest: CLL Treatment, Gilead CEO Sells, Acelity IPO http://seekingalpha.com/article/3470766-premarket-biotech-digest-cll-treatment-gilead-ceo-sells-acelity-ipo?source=feed Aug 27, 2015 - This article discusses latest advances in chronic lymphocytic leukemia.
5.85% To 43% Yields From 9 Sector-Leading Dividend Dogs As Of August 24 http://seekingalpha.com/article/3469956-5_85-percent-to-43-percent-yields-from-9-sector-leading-dividend-dogs-as-of-august-24?source=feed_all_articles Aug 27, 2015 - 30 top business sector-leading stocks ranked themselves by yield from 5.73% to 43.05% as of August 24.
Novartis' (NVS) Promacta Label Further Expanded in U.S. http://www.zacks.com/stock/news/187863/novartis-nvs-promacta-label-further-expanded-in-us?cid=CS-ZC-FT-187863 Aug 26, 2015 - Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
Premarket Biotech Digest: Valeant's M&A Prospects, Stocks Tumble, Novartis Promacta Extension http://seekingalpha.com/article/3464306-premarket-biotech-digest-valeants-m-and-a-prospects-stocks-tumble-novartis-promacta-extension?source=feed_sector_healthcare Aug 25, 2015 - This article discusses Valeant and EP Vantage's take on it.
Novartis to Buy Full Arzerra Rights from GlaxoSmithKline http://www.zacks.com/stock/news/187507/novartis-to-buy-full-arzerra-rights-from-glaxosmithkline?cid=CS-ZC-FT-187507 Aug 24, 2015 - Novartis (NVS) inked a deal with GlaxoSmithKline to acquire all remaining rights to Arzerra for up to $1 billion plus royalties.

Pages: 1...84858687888990

<<<Page 89